Weekly electronic patient-reported outcome monitoring with alert-based clinical follow-up is associated with clinically meaningful reductions in fatigue and better physical functioning among women receiving systemic treatment for metastatic breast cancer, according to a multicentre randomised clinical trial.
This open-label, randomised clinical trial, published in JAMA Oncology, was conducted at 52 academic and community breast cancer centres in Germany between May 2021 and February 2024.
Clinically meaningful deterioration identified by an algorithm triggered an automated alert to a trained nurse or physician, who was expected to telephone the patient within 48 hours.
At six months, adjusted mean fatigue scores were 54.5 (95% CI, 53.7- 55.4) with weekly monitoring and 59.9 (95% CI, 59.0-60.8) with usual care, giving a between-group difference of −5.4 T-score points (95% CI −6.6 to −4.1; p<0.001).
This exceeded the minimal clinically important difference of 3.3 points. Differences continued to favour the intervention at three, nine and 12 months.
【MORE】